Chicago Atlantic Real Estate Finance, Inc. (REFI) Earnings Call Transcript & Summary
May 7, 2025
Earnings Call Speaker Segments
Tripp Sullivan
executiveThanks, and good morning, everyone. I’d like to welcome you to the Chicago Atlantic Real Estate Finance conference call, where we’ll go over the company’s results. Joining us today are Peter Sack, our co-Chief Executive Officer; David Kite, our Chief Operating Officer; and Phillip Silverman, our Chief Financial Officer. We put out our results earlier this morning in our earnings press release, and you can find that in the best relations section of our website, together with our supplemental, which was filed with the SEC. A live audio webcast is available today; if you’re listening to a replay of this webcast, please note that what we say here reflects today only and won’t be updated after this call. During this call, some of our comments and statements may count as forward-looking statements under the meaning set by the securities laws, including statements about how our portfolio may perform in the future, our pipeline of possible loans and other investments, future dividends, and financing activities. Every forward-looking statement reflects Chicago Atlantic’s judgment as of the date of this conference call and carries risk and uncertainties that could make actual results differ materially from what we currently expect. We encourage investors to review carefully the various disclosures the company has made, including the risk and other information disclosures in the company’s filings with the SEC. We’ll also talk about certain non-GAAP measures, including but not limited to distributable earnings. Definitions of these non-GAAP measures and reconciliations to the most comparable GAAP measures are included in our filings with the SEC. I’ll now hand the call over to Peter Sack. Please go ahead.
Peter Sack
executiveThanks, Tripp. Morning, everybody. Here at Chicago Atlantic, credit and collateral come first, and we aim to bring value to the people we lend to by working together in an industry that keeps changing. We're a top player in cannabis lending, with a staff of sector specialists, originators, and underwriters. Right from the start, we've built our book on the assumption that things won't get better on the federal regulatory side. We watch the swings that happen in cannabis equity markets as hope for federal reform rises and falls. Our goal is to give investors returns with downside protection and steady yield no matter how short-lived the mood or how much related equity volatility there is; that very volatility pushes other sources of capital to leave or pull back. With so much uncertainty in this industry, we think Chicago Atlantic is a steady presence that borrowers and investors can rely on. We put money to work with consumer and product focused operators in limited license jurisdictions, using low leverage profiles, to back fundamentally sound growth plans; some quarters that means originations move at a strong clip and others, like Q1, move more slowly. Credit drives our investments, along with our capacity to safeguard principal and deliver strong risk adjusted returns. When those chances aren't available for a stretch, we think the correct call is to stay disciplined and patient. The cannabis pipeline across the Chicago Atlantic platform is now at $462 million. A number of well-run and well-capitalized operators will still need to handle upcoming maturities during the next 12 months, and we think we'll capture a fair share of those chances. As I've said before, our aim is to build a differentiated, low levered risk return profile. It avoids cannabis equity volatility and beats our industry agnostic mortgage rate peers. Picking up on the analysis we shared last quarter, I'm happy to say that in spite of all the volatility in the broader financial services market, we're still the number three top performing exchange listed mortgage rate; we have a slide in our supplemental that goes through this analysis. We're very proud of that result and we're aiming for number one. One last statistic. Since we began, we've beaten the median and average total return for all exchange listed mortgage rates by roughly 51% and 55%, respectively. David, over to you.
David Kite
executiveThanks, Peter. As of March 31, the outstanding principal across our loan book totaled $407 million, distributed among 30 portfolio companies, while the weighted average yield to maturity was 16.9%, compared with 17.2% during the fourth quarter — a change largely attributable to the restructuring of loan number nine. During the quarter, gross originations amounted to $4.4 million in principal funding, divided into $0.5 million for new borrowers and $3.9 million for existing ones, all via delayed draw term loan facilities. Offsetting that were sales and repayments totaling $9.2 million. As of March 31, 2025, fixed rate loans plus floating rate loans with floors at or above the current prime rate accounted for 71.2% of the portfolio. The other 28.8%, which remains floating, has no interest rate cap exposure at present levels. Even though uncertainty surrounding the rate outlook continues, as Peter noted earlier, we believe the portfolio is built to cushion the impact of declining interest rates while benefiting if rates rise, accomplished by adjusting the mix of floating and fixed rate loans and by obtaining elevated floors. At March 31, total leverage was 28% of book equity, a decrease from 34% as of December 31, 2024. Our consolidated debt service coverage ratio for the quarter was approximately 6.2 to 1, comfortably above the 1.35 to 1 covenant. At March 31, $38 million remained outstanding under our senior secured credit facility, and we had fully drawn the $50 million on our unsecured term loan. Currently, roughly $43 million is outstanding on the senior credit facility, with total liquidity of $65 million. Last, an update on loan number nine. As we mentioned last quarter, the administrative agent achieved key milestones in foreclosing on certain operating assets of the borrower associated with loan number nine. Related parties of the administrative agent successfully became affiliated with the Pennsylvania Department of Health as principals, giving them complete operational control of those assets for the lenders' benefit. The agent distributed the aggregate proceeds from the foreclosure — comprising the equity acquired through the UCC Article 9 sale plus the court ordered judgment awarded — to the company and the other co-lenders. Since the company is unable to hold equity investments in plant touching cannabis operations, it acquired new loans totaling approximately $16.5 million, still senior secured by the borrower's real estate assets, with interest accruing at a fixed 9% rate. The borrower's three dispensaries, which had been non-operational, have reopened, with the most recent opening occurring on April 30. REFI's new loan is senior secured and occupies the top of the capital structure. With the restructured assets being senior secured and operations now underway, we reversed approximately $1.2 million of the CECL reserve tied to loan number 9. Bringing operations to the level they ought to reach will take a certain amount of time. Even so, we believe that through reorganizing both our operations and the balance sheet, we could return this loan to accrual status before the year is out, by December 31, 2023. Now I'll turn it over to Phil.
Phillip Silverman
executiveThanks, David. Turning to the first quarter, net interest income reached $13 million, a 7.3% decrease compared with $14.1 million during the fourth quarter of 2024. That drop was driven mostly by reduced non-recurring prepayment make whole exit and structuring fees — $0.4 million in Q1 2025 against $1.5 million in Q4 2024 — plus the impact of a full quarter from the 50 basis point reductions to the prime rate that took place during the second half of the fourth quarter. Total interest expense in Q1, which includes non-cash amortization of financing costs, totaled about $2.1 million, consistent with Q4 2024. We had a full quarter of interest expense on our unsecured notes, which were closed in mid-October of last year and carry a 9% rate. Weighted average borrowings under our revolving loan — bearing interest at prime plus a margin tied to our leverage ratio — increased to $41.6 million, up from $23.3 million in the fourth quarter. As of today, roughly $67 million is still available under that revolver. Professional fees and general administrative expenses combined declined by about $300,000 compared with the prior quarter, primarily due to expense reimbursements from our manager: approximately $1.1 million in Q1 versus $1.4 million the quarter before. Our CECL reserve against loans held for investment was about $3.3 million on March 31, 2025, a decrease from $4.4 million on December 31, 2024. That decrease largely reflects the reversal of $1.2 million of credit loss related to loan number nine, which was restructured during Q1 2025, as David mentioned. Relative to size, our expected credit loss reserve comes to 83 basis points of the outstanding principal on loans held for investment. On a weighted average basis, real estate coverage throughout the portfolio was 1.1 times. In addition to real estate, our loans are secured by other collateral forms, including UCC-1 all asset liens on our borrower credit parties. Those other collateral types bolster overall credit quality and help keep loan-to-value ratios down. As of March 31, 2025, the loan-to-enterprise value ratio for our portfolio was 47.5%, calculated as the borrower's senior indebtedness divided by total collateral fair value. During the first quarter, we generated about $1 million of net proceeds from common stock issuance under our ATM program. The weighted average selling price net of commissions, $15.69, reflects a premium of approximately 5.5% to our March 31 book value. Distributable earnings per weighted average share was roughly $0.47 basic and $0.46 fully diluted in the first quarter, unchanged from the fourth quarter of last year. In April, we paid the first quarter dividend of $0.47 per common share that our Board declared in March 2025. Book value per common share stood at $14.87 on March 31, 2025, and $14.83 on December 31, 2024, having risen from $1,483 per common share as of December 31, 2024 to $1,487 per common share as of March 31, 2025. Once full dilution is taken into account, approximately 21.3 million common shares were outstanding on March 31, 2025, and we brought in almost $85 million in the fourth quarter. On last quarter's call, we communicated that our intention for tax year 2025 is to maintain a dividend payout ratio linked to basic distributable earnings per share in the range of 90% to 100%. If our taxable income were to require greater distributions than the standard quarterly dividend delivers so that we meet our taxable income obligations, we would anticipate addressing that gap via a special dividend distributed in the fourth quarter. Our net asset value stood at $1,483 per common share as of December 31, 2024, and reached $1,487 per common share as of March 31, 2025, while we generated almost $85 million in the fourth quarter. Operator, we're ready to take questions now.
Aaron Grey
analystMorning, and thanks a lot for taking the questions. My first one relates to the near-term pipeline, where you had $462 million; that still looks solid. I was hoping you could tell us how many opportunities sit in it and what phases they're at, plus how many have reached the later phases, so we can better gauge how that feeds into new originations in 2025. I realize guidance isn't something you give, but perhaps you could add a bit of incremental color about the kinds of attractive opportunities showing up in that pipeline — are they tilted more toward CapEx builds or M&A? Any detail along those lines would be welcome. Thank you.
Peter Sack
executiveAppreciate the question. As for the pipeline — it's mostly tied to CapEx — we anticipate deployments picking up pace during Q2 and Q3 of this year, though providing more specifics than that is tough.
Aaron Grey
analystAll right. No, that's really useful. Appreciate it, Peter. For my second question, I want to ask something at a broader level. Pricing pressure remains a significant issue across this industry. When you're underwriting, which pricing assumptions are you using? And this matters more and more now that certain markets that used to have limited licenses, Massachusetts being one, have grown up, with price points resembling those in open-license markets. So I'm just wondering whether the pricing assumption you build into your underwriting has changed compared with what you'd have used 1 or 2 years back. Thank you.
Peter Sack
executiveInteresting question. In our view, pricing in this industry has always been a moving target. Even across every state, there's a development curve, and pricing shifts as a state gets its medical program going — even a state with limited licenses gets its medical program going — then rolls out adult use, and that adult-use market grows up; and practically every jurisdiction experiences some version of price compression, some downward trajectory; it's just that the pace of that compression differs state by state, with some much slower than others. Take Massachusetts, for instance — across recent years, we cut back our exposure to that state considerably, though step by step, since we could see the pricing pressure coming; and that's among the advantages we enjoy as a lender, one of the tools available to us in this sector that an operator wouldn't have as much room to use, given a loan of fairly short duration. We can let maturity arrive, get repaid, and then choose not to put fresh capital into XYZ state, whereas pulling that off is far harder for an operator. So when we're — as we assess putting capital to work, current pricing and our sense of where that state falls along its price-compression trajectory are central to how we evaluate leverage and how we evaluate risk, and if we're able to spread that around, so much the better.
Aaron Grey
analystAll right, that's a big help, thanks for that call. I'll step out and rejoin the line later.
Chris Muller
analystHi everyone, I appreciate you fielding my questions. Perhaps to build a bit on what was asked earlier, what level of clarity do you have regarding repayments over the coming months, and ought we to anticipate some net portfolio growth during 2025? I'm not after any precise figures, just perhaps the overall direction.
Peter Sack
executiveWe're targeting net portfolio growth for 2025. A substantial volume of maturities land in 2025. For the bulk of them, we'll be fighting to refinance and preserve the borrower connection, since we think those assets are performing well, the companies have cut their leverage or hold strong appealing chances either to supply extra capital or to sustain a lending tie with them. Therefore, for the great majority of 2025 maturities, our goal will be to battle for the deal and refinance those positions through fresh facilities.
Chris Muller
analystUnderstood, that's quite useful. And I realize this topic keeps coming up and by now probably sounds repetitive, but it appears that discussions around rescheduling are gaining momentum once more after certain remarks from the new DEA nominee. So at a broad level, could you just explain how rescheduling might affect your operations if it truly happens?
Peter Sack
executiveWe would welcome rescheduling, and we would welcome more clarity regarding how overdue tax obligations from earlier years get handled moving forward. Clear guidance on those two items would be extremely beneficial for us since removing 280E prospectively boosts after-tax free cash flow across all of our borrowers substantially. It gives them greater downside protection for our debt facilities. It supplies more capital for expansion, delivers additional equity value and equity dollars along with cash flow capable of supporting further leverage, and ought to lift equity valuations across the broader market, which we anticipate would drive more M&A activity and capital expenditures. And on the whole, it removes the widespread market uncertainty that persists right now. That said, although we believe rescheduling will probably generate far more growth, opportunity, rising valuations, and more participants in cannabis equity markets, we expect that broader involvement from other lenders and debt capital within cannabis will require considerably more time. And demand additional reforms beyond merely rescheduling.
Chris Muller
analystUnderstood. And perhaps looking out further, would you figure that yields would mostly tighten, while leverage would climb, shifting toward that mortgage rate model that's more standard?
Peter Sack
executiveTo get yields to tighten, I believe you'd need to witness more players coming into the market. And when it comes just to rescheduling, I haven't yet observed meaningful proof of meaningful newcomers arriving, though we shall find out.
Chris Muller
analystThis is a really favorable situation for those who are already active here, and you all are performing excellently. So I appreciate you fielding the question.
Peter Sack
executiveThat's my view as well. Thank you. And one thing I would mention is that among the biggest companies trading on public markets, those are likely to be the ones that gain earliest from rescheduling as well as a reduced cost of capital, particularly when it comes to equity capital. As for the following tier — middle market businesses and growing lower middle market companies active here — capital providers will need a longer period, assuming any actually step forward, to offer meaningful new alternatives for operators of that size and profile.
Chris Muller
analystThat all sounds quite reasonable. I appreciate you letting us ask follow-ups once more.
Pablo Zuanic
analystThanks, and good morning to everybody. I apologize for returning to the topic of net portfolio growth, but regarding new fundings — I believe the figure for the first quarter was roughly $4 million, whereas during the entire prior year you reached $161 million, with the fourth quarter alone contributing just over 85. That's quite a significant shift when you look at the numbers, isn't it? Should we read this as a sign that your view on the industry's prospects for the coming three or six months has turned more conservative, or is that not necessarily the case? Then for the second question: since you won't provide guidance on portfolio growth, what ought we to expect for the entire year? I mean, just at a basic level, very modest portfolio growth — if you could give a bit more detail on that, please. Thank you.
Peter Sack
executiveThanks, Pablo. Our aim is to expand the portfolio, and to do so substantially over the course of the year. Q1 saw only a small amount of deployment. I believe two things caused that. The first was our own choosiness, and the second was caution, rather than choosiness, along with more careful deliberation among operators across the industry. During Q4 and Q1, cannabis stocks that trade publicly hit some of the cheapest levels the market has ever witnessed. That, I believe, has prompted many operators to reconsider what they need for capital planning and to reassess their expansion initiatives, holding off until certain unclear market factors shift before they commit to that next move. So I'd say it reflects two things: prudence and pickiness from us, plus prudence and pickiness from the operators in this sector, given the ambiguity surrounding the industry.
Pablo Zuanic
analystThat's clear, and I get it. That's useful context. I haven't yet gone through the 10Q in full, but could you discuss the unfunded commitments as of the quarter's end?
Peter Sack
executivePhil, do you want to handle that?
Phillip Silverman
executiveRight, absolutely. So Pablo, regarding that, we're looking at roughly $19.8 million in unfunded commitments. Under the credit agreements, those are allocated for specific purposes — in some instances tied to construction milestones, or other projects that the individual borrowers are considering down the road. So we'll only fund them once those conditions are satisfied. And with certain of them, there's discretion on our side as the lender before we actually put that money out, so the timing of deployment strikes me as somewhat uncertain.
Pablo Zuanic
analystUnderstood. Thanks. So, I want to draw an analogy to sale-leaseback deals, and I realize this is an entirely separate sector — we all observed what happened with IAPR farmacan. My sense is that IAPR worried a great deal that sitting down to negotiate in that case might establish a precedent. Of course, I recognize that reworking terms on the mortgage rate is simply part of how this business operates, correct? Even so, the manner in which you went about restructuring loan number 9 may have created something of a precedent affecting other credits in your portfolio, as seen from the borrower's point of view.
Peter Sack
executiveMy view is that no two situations are alike. Still, when it comes to loan number 9, I believe we demonstrated that we, as lenders, have the ability to see a restructuring through, take it all the way to completion, and provide support for the company's operations both while the restructuring was underway and as it emerged from it. We also showed that we are prepared to take those steps whenever circumstances require it. On top of that, I believe it demonstrates that extending credit within the cannabis industry — despite the uncertainty stemming from the lack of bankruptcy court access — can nevertheless be carried out in the manner one would anticipate lenders being able to carry it out when things go badly.
Pablo Zuanic
analystUnderstood, and just one more. From what I gather, a number of the officers at these companies also hold roles at the group level — they sit on the manager's team, if I have that right. What I'm trying to get at is this: when shareholders hear talk about the pipeline, correct? Often that pipeline figure sits at the Chicago Atlantic group level. And a portion of it will be directed toward new fundings allocated to the group, the private group, to the mortgage REIT, or perhaps now to the BDC, which is likewise a publicly listed vehicle. Could you explain how that allocation process actually functions in practice?
Peter Sack
executiveEveryone at Chicago Atlantic serves as an equal fiduciary across each of our funds. As a result, every opportunity that comes up gets an equal chance to be funded by each of the funds; that said, any individual fund, the REIT included, may choose not to take part in a deal should it fail to satisfy that vehicle's diversification requirements or other constraints that could render it ineligible to participate. So it's difficult. While an opportunity is being evaluated, it's only close to the end of that process that you can be certain about what portion of the pipeline, or what portion of a particular deal, would qualify as eligible and allocatable and is expected to go to one vehicle versus another — whether that's the mortgage REIT, the BDC, or some other vehicle. That's exactly why we give a total pipeline figure rather than a more specific, vehicle-by-vehicle pipeline number.
Pablo Zuanic
analystGot it. Thank you very much.
Operator
operatorThanks. It looks like we don't have any more questions. That brings our Q&A portion to a close. The conference is now finished. We appreciate you joining us for today's presentation. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Chicago Atlantic Real Estate Finance, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Chicago Atlantic Real Estate Finance, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Chicago Atlantic Real Estate Finance, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.